Stem Point Capital LP Immatics N.V. Call Options Transaction History
Stem Point Capital LP
- $340 Billion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding IMTX
# of Institutions
99Shares Held
76.6MCall Options Held
571KPut Options Held
210K-
Rtw Investments, LP New York, NY10MShares$109 Million1.94% of portfolio
-
Wellington Management Group LLP Boston, MA9.54MShares$104 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$87.8 Million2.72% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.43MShares$80.7 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$70 Million1.0% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $828M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...